Vision - To eliminate kidney cancer through collaboration and discovery
Kidney Cancer Research (KCRP) has been funded by the CDMRP for many years under various programs including the Peer Reviewed Medical Research Program, Tuberous Sclerosis Complex Research Program, and, most recently, by the Peer Reviewed Cancer Research Program (PRCRP). From FY10 through FY16, the PRCRP invested over $9.8M in kidney cancer research. In FY17 the US Congress directed $10M to kidney cancer research in the DoD appropriation, thus establishing the Kidney Cancer Research Program. The American Cancer Society estimates that in 2017 approximately 63,990 new cases of kidney cancer will occur and 14,400 people will die from some form of kidney cancer.1 There are three main types of kidney cancer: renal cell cancer (RCC), Wilms tumors, and transition cell cancer (TCC, also known as urothelial carcinomas).1 RCC is the most common type of kidney cancer, with the subtype Clear Cell RCC accounting for 66-75% of all RCC diagnoses.2 Wilms tumor is a type of kidney cancer diagnosed almost exclusively in children under 15 years of age. TCC is relatively rare, and accounts for 5-10% of kidney cancer cases.3 The five-year survival rate of kidney cancer patients diagnosed with stage I disease is 92.6%, while for patient diagnosed at stage II it is 66.7%.4 With a new program, the KCRP will be able to focus research into prevention, detection, and treatment as well as long term effects of treatment for kidney cancer.
Last updated Friday, September 15, 2017